ArticleEngineering in life sciences2019
Polishing approach with fully connected flow-through purification for therapeutic monoclonal antibody.
Article in Engineering in life sciences, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Novel method for production and purification of untagged pneumococcal surface protein A from clade 1.Applied microbiology and biotechnology · 2024Article
- Integration of a perfusion reactor and continuous precipitation in an entirely membrane-based process for antibody capture.Engineering in life sciences · 2023Article
- Microbial astaxanthin: from bioprocessing to the market recognition.Applied microbiology and biotechnology · 2023Review
- Design and optimization of membrane chromatography for monoclonal antibody charge variant separation.Biotechnology progress · 2022Article
- Analysis of filtration behavior using integrated column chromatography followed by virus filtration.Biotechnology and bioengineering · 2021Article
- A novel twin-column continuous chromatography approach for separation and enrichment of monoclonal antibody charge variants.Engineering in life sciences · 2021Article
- A common framework for integrated and continuous biomanufacturing.Biotechnology and bioengineering · 2021Review
- Monitoring bioactive and total antibody concentrations for continuous process control by surface plasmon resonance spectroscopy.Engineering in life sciences · 2019Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The biopharmaceutical industry is evolving toward process intensification that can offer increased productivity and improved economics without sacrificing process robustness. A semi-continuous downstream process linking purification/polishing unit operations in series can reduce or eliminate intermediate holding tanks and reduce overall processing time. Accordingly, we have developed a therapeutic monoclonal antibody polishing template comprised of a connected flow-through polishing technologies that include activated carbon, cation exchange, and anion-exchange chromatography. In this report, we evaluated fully-connected pool-less polishing with three flow-through technologies, operating as a single skid to streamline and improve an mAb purification platform. Laboratory-scale pool-less processing was achieved without utilizing in-line pH adjustment and conductivity dilution based on the previously optimized single process parameter. Two connected flow-through configurations of polishing steps were evaluated: a two-step process using anion exchange and cation exchange and a three step process using activated carbon, anion exchange and cation exchange chromatography. Laboratory-scale proof of concept studies showed comparable performance between the batch purification process and the pool-less process configuration. Three step polishing highly intensified the processes and provided higher process loading and achieved bulk drug specification with higher impurity clearance (>95%) and high overall mAb yield (>95%).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.